

Docket: 7003/40
US Pat. Appln. No. 10/539,874

CLAIMS:

1. (Previously Presented) A method for treating tumor diseases in which TRPM8 is overexpressed, comprising administration of a physiologically active dose of a pharmaceutical composition comprising a TRPM8-activating substance or mixtures containing a TRPM8-activating substance
2. (Previously Presented) The method of claim 1, wherein the tumor disease is prostate cancer.
3. (Previously Presented) The method of claim 1, wherein the substance is selected from the group consisting of menthol, menthyl derivatives, pyrrolidinyl derivatives of furanone, icilin, icilin derivatives and mixtures of these substances.
4. (Previously Presented) The method of claim 1, wherein the substance or mixture of such substances is galenically prepared with additives comprising carriers, binding agents, coating agents, bursting agents, swelling agents, sliding agents, lubricants, flavoring substances, sweeteners or solution promoters.
5. (Previously Presented) A pharmaceutical composition for the treatment of tumor diseases comprising a TRPM8 activating substance or a substance that is selected from the group consisting of menthol, menthyl derivatives, pyrrolidinyl derivatives of furanone, icilin, icilin derivatives and mixtures of these substances, and one or more additives prepared galenically for intravenous, intraperitoneal or intramuscular injection or infusion.
6. (Previously Presented) The pharmaceutical composition of claim 5, in which the dose is set in the range from 0.1 to 1000 mg/kg body weight per day, divided into 1 to 10 dosage units.
7. (Previously Presented) The pharmaceutical composition of claim 5, in which the composition is prepared for continuous or discontinuous periodical administration over a time interval of at

Docket: 7003/40
US Pat. Appln. No. 10/539,874
least 2 weeks.

8. (Previously Presented) A method for the treatment of tumor diseases, comprising prostate cancer, in which a patient suffering from the disease is given a physiologically active dose of a TRPM8-inhibiting substance, comprising a pharmaceutical composition according to one of claims 5, 6, 7, 10 or 11.

9. (Previously Presented) The method of claim 2, wherein the substance is selected from the group consisting of menthol, menthyl derivatives, pyrrolidinyl derivatives of furanone, icilin, icilin derivatives and mixtures of these substances.

10. (Previously Presented) The pharmaceutical composition of claim 6, wherein the dosage is 1 to 100 mg/kg body weight per day, divided into 1 to 10 dosage units.

11. (Previously Presented) The pharmaceutical composition of claim 6, wherein the composition is prepared for continuous or discontinuous periodical administration over a time interval of at least 2 weeks.

12. (Previously Presented) The pharmaceutical composition of claim 7, wherein the time interval is at least 8 weeks.

13. (Previously Presented) The pharmaceutical composition of claim 11, wherein the time interval is at least 8 weeks.

14. (Previously Presented) The method of claim 1, wherein the tumor disease comprises neuroendocrine tumors comprising tumors of the gastrointestinal tract or respiratory organs.